(NYSE:ABBV) by 610.2% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 10,000 shares of the company's stock at the end of the first quarter. Country Club Trust Company n.a. increased its position in shares of AbbVie by 0.6% in the first quarter. Founders Capital Management's holdings in AbbVie were worth $3,361,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in ABBV. Two Sigma Securities LLC increased its stake in shares of AbbVie by 610.2% in the first quarter. Shares were disposed in a price range of $71.00, amounting $13,712,301.00. after the closing of the transaction the chairman has an ownership of 469,623 stocks in the company, worth at $33,343,233. Finally, Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $137,000. It also reduced its holding in Ishares S&P Global Infrastrucure (IGF) by 20,417 shares in the quarter, leaving it with 93,059 shares, and cut its stake in T Rowe Price Group Inc (NASDAQ:TROW). Atwood & Palmer Inc. boosted its stake in shares of AbbVie by 1,333.3% in the first quarter. The firm owned 14,070 shares of the company's stock after selling 2,647 shares during the period.
WARNING: "AbbVie Inc. (NYSE:ABBV) Stake Increased by Two Sigma Securities LLC" was originally reported by Week Herald and is the sole property of of Week Herald. During the same quarter previous year, the company earned $1.26 earnings per share. Moreover, Inv Management Of Virginia Ltd Llc has 1.4% invested in AbbVie Inc (NYSE:ABBV) for 93,383 shares. Oakbrook Invests Llc reported 0.07% of its portfolio in AbbVie Inc (NYSE:ABBV). 3,248,300 shares of the company traded hands. AbbVie has a 12-month low of $55.06 and a 12-month high of $75.04. The stock has a market capitalization of $112.59 billion, a P/E ratio of 17.37 and a beta of 1.50. The stock has a 50 day moving average of $72.05 and a 200 day moving average of $66.76.
AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The company had revenue of $6.94 billion during the quarter, compared to the consensus estimate of $6.93 billion. During the same quarter in the prior year, the company earned $1.26 EPS. The business's revenue for the quarter was up 7.6% compared to the same quarter past year. Clarivest Asset Mgmt Limited Liability has 0.65% invested in AbbVie Inc (NYSE:ABBV) for 388,057 shares. Investors of record on Friday, July 14th will be paid a $0.64 dividend. The ex-dividend date is Wed, Jul 12th.
Among 3 analysts covering EKF Diagnostics Holdings PLC (LON:EKF), 2 have Buy rating, 0 Sell and 1 Hold. AbbVie's dividend payout ratio is now 62.90%.
COPYRIGHT VIOLATION NOTICE: This article was published by Rincon Hill News and is owned by of Rincon Hill News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of US & global copyright & trademark legislation. The legal version of this piece can be read at https://stocknewstimes.com/2017/08/12/abbvie-abbv-receiving-somewhat-critical-press-coverage-analysis-shows-updated-updated.html.
A number of brokerages recently commented on ABBV. Leerink Swann restated a "market perform" rating on shares of AbbVie in a research note on Thursday, June 22nd. BMO Capital Markets reaffirmed a "hold" rating and set a $63.00 target price on shares of AbbVie in a research report on Tuesday, April 18th. Finally, BidaskClub lowered shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 28th. Piper Jaffray Companies reiterated a "buy" rating and set a $85.00 price objective on shares of AbbVie in a research report on Thursday, August 3rd. On Wednesday, June 7 the stock rating was maintained by Credit Suisse with "Hold". Nine research experts recommended the company shares with a hold recommendation, around seven has issued a buy recommendation and 1 has given a strong buy recommendation to the firms shares. the share has a average recommendation of "Buy" and an average price objective of $74.66. The stock of AbbVie Inc (NYSE:ABBV) has "Buy" rating given on Tuesday, February 23 by Citigroup. Also, Chairman Richard A. Gonzalez sold 71,235 shares of AbbVie stock in a transaction on Friday, May 19th. The shares were sold at an average price of $65.49, for a total transaction of $4,665,180.15. $2.50M worth of stock was sold by CHASE WILLIAM J on Thursday, May 18. The shares were sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the sale, the chief financial officer now owns 209,043 shares of the company's stock, valued at $13,660,960.05. American National Bank now owns 2,471 shares of the company's stock worth $161,000 after buying an additional 299 shares during the last quarter.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Electric segment includes the production, transmission, distribution and sale of electric energy in Minnesota, North Dakota and South Dakota by Otter Tail Power Company. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Want to see what other hedge funds are holding ABBV?